GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Long-Term Capital Lease Obligation

Boiron (FRA:BON) Long-Term Capital Lease Obligation : €6.2 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Boiron Long-Term Capital Lease Obligation?

Boiron's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.2 Mil.

Boiron's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (€5.2 Mil) to Jun. 2023 (€7.2 Mil) but then declined from Jun. 2023 (€7.2 Mil) to Dec. 2023 (€6.2 Mil).

Boiron's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€5.4 Mil) to Dec. 2022 (€5.2 Mil) but then increased from Dec. 2022 (€5.2 Mil) to Dec. 2023 (€6.2 Mil).


Boiron Long-Term Capital Lease Obligation Historical Data

The historical data trend for Boiron's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Long-Term Capital Lease Obligation Chart

Boiron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.24 5.62 5.37 5.17 6.21

Boiron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 5.69 5.17 7.21 6.21

Boiron  (FRA:BON) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Boiron Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Boiron's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Boiron (FRA:BON) Business Description

Industry
Traded in Other Exchanges
Address
2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.